Trials for a Two-Dose COVID-19 Vaccine to be Tested by Reliance Life Sciences
The drug regulatory authorities authorised Reliance Life Sciences’ proposal to conduct clinical trials of its recombinant protein-based Covid-19 vaccine candidate on Thursday.
Reliance Life Sciences is part of India’s largest private-sector organisation. Reliance had requested permission from the agency to undertake a Phase 1 trial of its proposed two-dose vaccination. Reliance hopes to learn about medication safety, tolerability, pharmacokinetics, and mechanism of action in Phase 1.
According to a source familiar with the situation, Phase 1 trials typically last 58 days, after which Reliance might apply for Phase 2 and 3 trials. Reliance Life Sciences is yet to make an official announcement. Reliance’s vaccine initiatives come at a time when the country’s vaccination rate is increasing.
Pic Courtesy: google/ images are subject to copyright
